212 related articles for article (PubMed ID: 38335281)
21. Sex and Age Differences in a Progressive Synucleinopathy Mouse Model.
Lamontagne-Proulx J; Coulombe K; Morissette M; Rieux M; Calon F; Di Paolo T; Soulet D
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371557
[TBL] [Abstract][Full Text] [Related]
22. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons.
Chung CY; Khurana V; Auluck PK; Tardiff DF; Mazzulli JR; Soldner F; Baru V; Lou Y; Freyzon Y; Cho S; Mungenast AE; Muffat J; Mitalipova M; Pluth MD; Jui NT; Schüle B; Lippard SJ; Tsai LH; Krainc D; Buchwald SL; Jaenisch R; Lindquist S
Science; 2013 Nov; 342(6161):983-7. PubMed ID: 24158904
[TBL] [Abstract][Full Text] [Related]
23. Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity.
Hu D; Sun X; Liao X; Zhang X; Zarabi S; Schimmer A; Hong Y; Ford C; Luo Y; Qi X
Acta Neuropathol; 2019 Jun; 137(6):939-960. PubMed ID: 30877431
[TBL] [Abstract][Full Text] [Related]
24. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus.
Devine MJ; Ryten M; Vodicka P; Thomson AJ; Burdon T; Houlden H; Cavaleri F; Nagano M; Drummond NJ; Taanman JW; Schapira AH; Gwinn K; Hardy J; Lewis PA; Kunath T
Nat Commun; 2011 Aug; 2():440. PubMed ID: 21863007
[TBL] [Abstract][Full Text] [Related]
25. Lysophosphatidylcholine acyltransferase 1 promotes pathology and toxicity in two distinct cell-based alpha-synuclein models.
Nicholatos JW; Tran D; Liu Y; Hirst WD; Weihofen A
Neurosci Lett; 2022 Feb; 772():136491. PubMed ID: 35108590
[TBL] [Abstract][Full Text] [Related]
26. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
27. N-Terminal Acetylation Affects α-Synuclein Fibril Polymorphism.
Watson MD; Lee JC
Biochemistry; 2019 Sep; 58(35):3630-3633. PubMed ID: 31424918
[TBL] [Abstract][Full Text] [Related]
28. Roles of α-Synuclein and Disease-Associated Factors in
Suzuki M; Sango K; Nagai Y
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163450
[TBL] [Abstract][Full Text] [Related]
29. Phosphatidylinositol-3,4,5-trisphosphate interacts with alpha-synuclein and initiates its aggregation and formation of Parkinson's disease-related fibril polymorphism.
Choong CJ; Aguirre C; Kakuda K; Beck G; Nakanishi H; Kimura Y; Shimma S; Nabekura K; Hideshima M; Doi J; Yamaguchi K; Nakajima K; Wadayama T; Hayakawa H; Baba K; Ogawa K; Takeuchi T; Badawy SMM; Murayama S; Nagano S; Goto Y; Miyanoiri Y; Nagai Y; Mochizuki H; Ikenaka K
Acta Neuropathol; 2023 May; 145(5):573-595. PubMed ID: 36939875
[TBL] [Abstract][Full Text] [Related]
30. Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models.
Drobny A; Boros FA; Balta D; Prieto Huarcaya S; Caylioglu D; Qazi N; Vandrey J; Schneider Y; Dobert JP; Pitcairn C; Mazzulli JR; Zunke F
Transl Neurodegener; 2023 Jun; 12(1):31. PubMed ID: 37312133
[TBL] [Abstract][Full Text] [Related]
31. Abnormal accumulation of lipid droplets in neurons induces the conversion of alpha-Synuclein to proteolytic resistant forms in a Drosophila model of Parkinson's disease.
Girard V; Jollivet F; Knittelfelder O; Celle M; Arsac JN; Chatelain G; Van den Brink DM; Baron T; Shevchenko A; Kühnlein RP; Davoust N; Mollereau B
PLoS Genet; 2021 Nov; 17(11):e1009921. PubMed ID: 34788284
[TBL] [Abstract][Full Text] [Related]
32. Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy.
Sorrentino ZA; Hass E; Vijayaraghavan N; Gorion KM; Riffe CJ; Dhillon JS; Giasson BI
Neurosci Lett; 2020 Jul; 732():135017. PubMed ID: 32371157
[TBL] [Abstract][Full Text] [Related]
33. A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity.
Nuber S; Chung CY; Tardiff DF; Bechade PA; McCaffery TD; Shimanaka K; Choi J; Chang B; Raja W; Neves E; Burke C; Jiang X; Xu P; Khurana V; Dettmer U; Fanning S; Rhodes KJ; Selkoe DJ; Scannevin RH
Neurotherapeutics; 2022 Apr; 19(3):1018-1036. PubMed ID: 35445353
[TBL] [Abstract][Full Text] [Related]
34. Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells.
Oliveira LM; Falomir-Lockhart LJ; Botelho MG; Lin KH; Wales P; Koch JC; Gerhardt E; Taschenberger H; Outeiro TF; Lingor P; Schüle B; Arndt-Jovin DJ; Jovin TM
Cell Death Dis; 2015 Nov; 6(11):e1994. PubMed ID: 26610207
[TBL] [Abstract][Full Text] [Related]
35. α-Synuclein Oligomers Induce Glutamate Release from Astrocytes and Excessive Extrasynaptic NMDAR Activity in Neurons, Thus Contributing to Synapse Loss.
Trudler D; Sanz-Blasco S; Eisele YS; Ghatak S; Bodhinathan K; Akhtar MW; Lynch WP; Piña-Crespo JC; Talantova M; Kelly JW; Lipton SA
J Neurosci; 2021 Mar; 41(10):2264-2273. PubMed ID: 33483428
[TBL] [Abstract][Full Text] [Related]
36. Isogenic human SNCA gene dosage induced pluripotent stem cells to model Parkinson's disease.
Zafar F; Nallur Srinivasaraghavan V; Yang Chen M; Alejandra Morato Torres C; Schüle B
Stem Cell Res; 2022 Apr; 60():102733. PubMed ID: 35263701
[TBL] [Abstract][Full Text] [Related]
37. α-Synuclein Decreases the Abundance of Proteasome Subunits and Alters Ubiquitin Conjugates in Yeast.
Popova B; Galka D; Häffner N; Wang D; Schmitt K; Valerius O; Knop M; Braus GH
Cells; 2021 Aug; 10(9):. PubMed ID: 34571878
[TBL] [Abstract][Full Text] [Related]
38. Breaking down and building up alpha-synuclein: An insight on its N-terminal domain.
Peqini K; Attanasio S; Feni L; Cappelletti G; Pellegrino S
J Pept Sci; 2024 Apr; 30(4):e3556. PubMed ID: 38037257
[TBL] [Abstract][Full Text] [Related]
39. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway.
Park JH; Burgess JD; Faroqi AH; DeMeo NN; Fiesel FC; Springer W; Delenclos M; McLean PJ
Mol Neurodegener; 2020 Jan; 15(1):5. PubMed ID: 31931835
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.
Diepenbroek M; Casadei N; Esmer H; Saido TC; Takano J; Kahle PJ; Nixon RA; Rao MV; Melki R; Pieri L; Helling S; Marcus K; Krueger R; Masliah E; Riess O; Nuber S
Hum Mol Genet; 2014 Aug; 23(15):3975-89. PubMed ID: 24619358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
